First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib ...
(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...
The PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical ...
Could a daily pill after chemoradiation keep lung cancer from returning? The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback